Diabetes, Vol 45, Issue 9 1279-1281, Copyright © 1996 by American Diabetes Association

ARTICLES

Missense mutation of amylin gene (S20G) in Japanese NIDDM patients

S Sakagashira, T Sanke, T Hanabusa, H Shimomura, S Ohagi, KY Kumagaye, K Nakajima and K Nanjo
First Department of Medicine, Wakayama University of Medical Science, Japan.

Many studies suggest that amylin, which is cosecreted with insulin from islet beta-cells, is a biologically active peptide and modulates plasma glucose levels. We therefore scanned the amylin gene for mutations in 294 Japanese NIDDM patients by single-strand conformational polymorphism, and we found a single heterozygous missense mutation (Ser-->Gly at position 20: S20G mutation) in 12 NIDDM patients (frequency 4.1%). None of the 187 nondiabetic subjects or 59 IDDM patients had the mutation. Of 12 patients carrying the mutation, 8 were diagnosed as having NIDDM at a relatively early age (< or = 35 years), and they had severe diabetes and strong family histories of late-onset NIDDM. On the other hand, the remaining four patients were diagnosed as having NIDDM after age 51, and they had mild diabetes without family histories of diabetes. In high-performance liquid chromatography analysis, a small amount (16%) of amylin immunoreactivity appeared in the position corresponding to normal amylin and a much larger amount (84%) appeared in the position corresponding to mutant amylin. These findings suggest that the S20G mutation of the amylin gene may play a partial role in the pathogenesis of early-onset NIDDM in the Japanese population and may also provide an important model to investigate the true physiological action of amylin.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C.-j. Huang, C.-y. Lin, L. Haataja, T. Gurlo, A. E. Butler, R. A. Rizza, and P. C. Butler High Expression Rates of Human Islet Amyloid Polypeptide Induce Endoplasmic Reticulum Stress Mediated {beta}-Cell Apoptosis, a Characteristic of Humans With Type 2 but Not Type 1 Diabetes Diabetes, August 1, 2007; 56(8): 2016 - 2027. [Abstract] [Full Text] [PDF]

				R. L. Hull, G. T. Westermark, P. Westermark, and S. E. Kahn Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3629 - 3643. [Abstract] [Full Text] [PDF]

				B. O'Nuallain, A. D. Williams, P. Westermark, and R. Wetzel Seeding Specificity in Amyloid Growth Induced by Heterologous Fibrils J. Biol. Chem., April 23, 2004; 279(17): 17490 - 17499. [Abstract] [Full Text] [PDF]

				H. T. Blumenthal Amyloidosis: A Universal Disease of Aging? J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2004; 59(4): M361 - M369. [Full Text] [PDF]

				M. C.Y. Ng, S.-C. Lee, G. T.C. Ko, J. K.Y. Li, W.-Y. So, Y. Hashim, A. H. Barnett, I. R. Mackay, J. A.J.H. Critchley, C. S. Cockram, et al. Familial Early-Onset Type 2 Diabetes in Chinese Patients: Obesity and genetics have more significant roles than autoimmunity Diabetes Care, April 1, 2001; 24(4): 663 - 671. [Abstract] [Full Text]

				S. Sakagashira, H. J. Hiddinga, K. Tateishi, T. Sanke, T. Hanabusa, K. Nanjo, and N. L. Eberhardt S20G Mutant Amylin Exhibits Increased in Vitro Amyloidogenicity and Increased Intracellular Cytotoxicity Compared to Wild-Type Amylin Am. J. Pathol., December 1, 2000; 157(6): 2101 - 2109. [Abstract] [Full Text] [PDF]

				H. J. Hiddinga and N. L. Eberhardt Intracellular Amyloidogenesis by Human Islet Amyloid Polypeptide Induces Apoptosis in COS-1 Cells Am. J. Pathol., April 1, 1999; 154(4): 1077 - 1088. [Abstract] [Full Text] [PDF]

				L. M. 't Hart, R. P. Stolk, J. M. Dekker, G. Nijpels, D. E. Grobbee, R. J. Heine, and J. A. Maassen Prevalence of Variants in Candidate Genes for Type 2 Diabetes Mellitus in The Netherlands: The Rotterdam Study and the Hoorn Study J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 1002 - 1006. [Abstract] [Full Text]